Plant Advanced Technologies SA (ALPAT.PA)
EUR 11.7
(-2.5%)
EUR 11.7
(-2.5%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 72.53 Thousand EUR | 95.58% |
| 2022 | -807 Thousand EUR | 64.13% |
| 2021 | -1.26 Million EUR | -2.13% |
| 2020 | -819 Thousand EUR | -98.95% |
| 2019 | -854.11 Thousand EUR | -64755.26% |
| 2018 | 681.53 Thousand EUR | -17.01% |
| 2017 | -1 Million EUR | -13.78% |
| 2016 | -1.27 Million EUR | -59.08% |
| 2015 | -702.01 Thousand EUR | -24.51% |
| 2014 | -674.89 Thousand EUR | -100.08% |
| 2013 | -73.48 Thousand EUR | 464.06% |
| 2012 | 136.67 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 FY | - EUR | 95.58% |
| 2023 Q2 | - EUR | 0.0% |
| 2022 Q4 | 899 Thousand EUR | 0.0% |
| 2022 FY | - EUR | 64.13% |
| 2022 Q2 | -1.7 Million EUR | 0.0% |
| 2021 Q4 | -927 Thousand EUR | 0.0% |
| 2021 FY | - EUR | -2.13% |
| 2021 Q2 | -1.47 Million EUR | 0.0% |
| 2020 Q4 | -327.45 Thousand EUR | 0.0% |
| 2020 FY | - EUR | -98.95% |
| 2020 Q2 | -899.38 Thousand EUR | 0.0% |
| 2019 FY | - EUR | -64755.26% |
| 2019 Q4 | -320.27 Thousand EUR | 0.0% |
| 2019 Q2 | -787.08 Thousand EUR | 0.0% |
| 2018 Q2 | -858.15 EUR | 0.0% |
| 2018 Q4 | -849.25 EUR | 0.0% |
| 2018 FY | - EUR | -17.01% |
| 2017 Q4 | -418.24 EUR | 0.0% |
| 2017 FY | - EUR | -13.78% |
| 2017 Q2 | -1040.97 EUR | 0.0% |
| 2016 Q2 | -1330.71 EUR | 0.0% |
| 2016 FY | - EUR | -59.08% |
| 2016 Q4 | 48.20 EUR | 0.0% |
| 2015 FY | - EUR | -24.51% |
| 2015 Q4 | -26.51 EUR | 0.0% |
| 2015 Q2 | -779.71 EUR | 0.0% |
| 2014 FY | - EUR | -100.08% |
| 2014 Q2 | -669.89 EUR | 0.0% |
| 2014 Q4 | 22.36 EUR | 0.0% |
| 2013 Q1 | 48.69 Thousand EUR | 0.0% |
| 2013 Q3 | 48.69 Thousand EUR | 17895.33% |
| 2013 Q4 | 163.46 EUR | -99.66% |
| 2013 FY | - EUR | 464.06% |
| 2013 Q2 | -273.66 EUR | -100.56% |
| 2012 Q2 | 76.67 Thousand EUR | 0.0% |
| 2012 Q3 | 76.67 Thousand EUR | 0.0% |
| 2012 Q4 | 48.69 Thousand EUR | -36.48% |
| 2012 FY | - EUR | 0.0% |
| 2012 Q1 | 76.67 Thousand EUR | 0.0% |
| 2011 Q4 | 76.67 Thousand EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | 102.205% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 100.054% |
| Adocia SA | -22.73 Million EUR | 100.319% |
| Aelis Farma SA | -6.34 Million EUR | 101.143% |
| Biophytis S.A. | -13.8 Million EUR | 100.525% |
| Advicenne S.A. | -6.24 Million EUR | 101.162% |
| genOway Société anonyme | 6.35 Million EUR | 98.858% |
| IntegraGen SA | -52.5 Thousand EUR | 238.144% |
| Medesis Pharma S.A. | -3.84 Million EUR | 101.886% |
| Neovacs S.A. | -8.44 Million EUR | 100.858% |
| NFL Biosciences SA | -4.04 Million EUR | 101.791% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | 102.524% |
| Sensorion SA | -22.31 Million EUR | 100.325% |
| Theranexus Société Anonyme | -7.38 Million EUR | 100.982% |
| TME Pharma N.V. | -5.07 Million EUR | 101.43% |
| Valbiotis SA | -6.95 Million EUR | 101.043% |
| TheraVet SA | -517.33 Thousand EUR | 114.02% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 100.383% |
| argenx SE | -199.5 Million EUR | 100.036% |
| BioSenic S.A. | -6.79 Million EUR | 101.067% |
| Celyad Oncology SA | -7.76 Million EUR | 100.934% |
| DBV Technologies S.A. | -79.53 Million EUR | 100.091% |
| Galapagos NV | 51.03 Million EUR | 99.858% |
| Genfit S.A. | -28.05 Million EUR | 100.259% |
| GeNeuro SA | -14.31 Million EUR | 100.507% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 100.484% |
| Innate Pharma S.A. | -7.57 Million EUR | 100.957% |
| Inventiva S.A. | -101.84 Million EUR | 100.071% |
| MaaT Pharma SA | -19.74 Million EUR | 100.367% |
| MedinCell S.A. | -20.04 Million EUR | 100.362% |
| Nanobiotix S.A. | -34.01 Million EUR | 100.213% |
| Onward Medical N.V. | -35.23 Million EUR | 100.206% |
| Oryzon Genomics S.A. | -4.43 Million EUR | 101.636% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 100.312% |
| Oxurion NV | -16.72 Million EUR | 100.434% |
| Pharming Group N.V. | 4.98 Million EUR | 98.544% |
| Poxel S.A. | -12.17 Million EUR | 100.596% |
| GenSight Biologics S.A. | -21.73 Million EUR | 100.334% |
| Transgene SA | -27.02 Million EUR | 100.268% |
| Financière de Tubize SA | 184.57 Thousand EUR | 60.703% |
| UCB SA | 1.26 Billion EUR | 99.994% |
| Valneva SE | -64.51 Million EUR | 100.112% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 100.256% |